Literature DB >> 16714381

p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors.

William M Keyes1, Hannes Vogel, Maranke I Koster, Xuecui Guo, Yi Qi, Kristin M Petherbridge, Dennis R Roop, Allan Bradley, Alea A Mills.   

Abstract

Homology between p63 and p53 has suggested that these proteins might function similarly. However, the majority of data from human tumors have not supported a similar role for p63 in tumor suppression. To investigate this issue, we studied spontaneous tumorigenesis in p63+/- mice in both WT and p53-compromised backgrounds. We found that p63+/- mice were not tumor prone and mice heterozygous for both p63 and p53 had fewer tumors than p53+/- mice. The rare tumors that developed in mice with compromised p63 were also distinct from those of p53+/- mice. Furthermore, p63+/- mice were not prone to chemically induced tumorigenesis, and p63 expression was maintained in carcinomas. These findings demonstrate that, in agreement with data from human tumors, p63 plays a markedly different biological role in cancer than p53.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714381      PMCID: PMC1482510          DOI: 10.1073/pnas.0602477103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  p63 and the epithelial stem cell: more than status quo?

Authors:  Frank McKeon
Journal:  Genes Dev       Date:  2004-03-01       Impact factor: 11.361

2.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.

Authors:  A Yang; M Kaghad; Y Wang; E Gillett; M D Fleming; V Dötsch; N C Andrews; D Caput; F McKeon
Journal:  Mol Cell       Date:  1998-09       Impact factor: 17.970

3.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

4.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

Review 5.  Multistage carcinogenesis in mouse skin.

Authors:  J DiGiovanni
Journal:  Pharmacol Ther       Date:  1992       Impact factor: 12.310

Review 6.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

Review 7.  p63 and p73: roles in development and tumor formation.

Authors:  Ute M Moll; Neda Slade
Journal:  Mol Cancer Res       Date:  2004-07       Impact factor: 5.852

8.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

9.  Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.

Authors:  C J Kemp; L A Donehower; A Bradley; A Balmain
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

10.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53.

Authors:  M Osada; M Ohba; C Kawahara; C Ishioka; R Kanamaru; I Katoh; Y Ikawa; Y Nimura; A Nakagawara; M Obinata; S Ikawa
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  41 in total

1.  p63 maintains keratinocyte proliferative capacity through regulation of Skp2-p130 levels.

Authors:  Simon S McDade; Daksha Patel; Dennis J McCance
Journal:  J Cell Sci       Date:  2011-04-21       Impact factor: 5.285

Review 2.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

3.  Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation.

Authors:  Yingchun Li; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

4.  TRP63/TP63 loss accelerates skin tumorigenesis through activation of Wnt/β-catenin signaling.

Authors:  Senthilnath Lakshmanachetty; Velmurugan Balaiya; Linda K Johnson; Maranke I Koster
Journal:  J Dermatol Sci       Date:  2018-06-01       Impact factor: 4.563

5.  A rare association of B cell lymphoma and ectodermal dysplasia presenting with protein-losing enteropathy.

Authors:  Mohamed Yousha Yousuf; Faraz Imran; Andrew Davis
Journal:  BMJ Case Rep       Date:  2009-02-27

Review 6.  The p53 family and programmed cell death.

Authors:  E C Pietsch; S M Sykes; S B McMahon; M E Murphy
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

7.  Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63.

Authors:  Bridget E Ferguson-Yates; Hongyan Li; Tiffany K Dong; Jennifer L Hsiao; Dennis H Oh
Journal:  Carcinogenesis       Date:  2007-11-04       Impact factor: 4.944

Review 8.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

9.  Role of p63 in Development, Tumorigenesis and Cancer Progression.

Authors:  Johann Bergholz; Zhi-Xiong Xiao
Journal:  Cancer Microenviron       Date:  2012-07-31

10.  p63 promotes cell survival through fatty acid synthase.

Authors:  Venkata Sabbisetti; Arianna Di Napoli; Apryle Seeley; Angela M Amato; Esther O'Regan; Musie Ghebremichael; Massimo Loda; Sabina Signoretti
Journal:  PLoS One       Date:  2009-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.